This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
ACADPositive Net Change ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
NVOPositive Net Change ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
ZTSPositive Net Change ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals vaccines
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
VRTXNegative Net Change HALOPositive Net Change CRSPPositive Net Change RPTXPositive Net Change
biotechs
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
by Zacks Equity Research
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
BMRNPositive Net Change HALOPositive Net Change IMTXPositive Net Change TRDAPositive Net Change
biotechs earnings medical pharmaceuticals
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
by Zacks Equity Research
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
REGNNegative Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change GILDNegative Net Change VTRSNegative Net Change
biotechs medical pharmaceuticals
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
JAZZPositive Net Change AXSMPositive Net Change ANIXPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs earnings-preview medical pharmaceuticals vaccines
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.
UTHRPositive Net Change HALOPositive Net Change RPTXPositive Net Change
biotechs earnings
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
UTHRPositive Net Change HALOPositive Net Change PBYIPositive Net Change RPTXPositive Net Change
biotechs earnings
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
by Zacks Equity Research
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
VRTXNegative Net Change HALOPositive Net Change ADMAPositive Net Change CRSPPositive Net Change
biotechs
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.
AZNPositive Net Change GSKPositive Net Change BIIBPositive Net Change IONSNegative Net Change
biotechs
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
REGNNegative Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
by Ekta Bagri
While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.
GSKPositive Net Change GILDNegative Net Change MRUSPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.
REGNNegative Net Change RAREPositive Net Change ANIXPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Stocks With Recent Price Strength in a Volatile Market
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are KNSA, HNI, AEYE, BCPC, GRC.
GRCPositive Net Change BCPCPositive Net Change HNIPositive Net Change AEYEPositive Net Change KNSAPositive Net Change
basic-materials biotechs business-services industrial-products internet
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.
UTHRPositive Net Change HALOPositive Net Change AMRNPositive Net Change RPTXPositive Net Change
biotechs earnings
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
by Ekta Bagri
Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
GSKPositive Net Change BIIBPositive Net Change BMYNegative Net Change VTVTPositive Net Change
biotechnology biotechs pharmaceuticals
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
BIIBPositive Net Change MRNAPositive Net Change DNLIPositive Net Change
biotechs
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
MRKPositive Net Change MRNAPositive Net Change HALOPositive Net Change TRDAPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
APLSPositive Net Change ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.
JNJPositive Net Change NVOPositive Net Change TEVANegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
by Zacks Equity Research
Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
REGNNegative Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
by Ekta Bagri
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
VRTXNegative Net Change PRMEPositive Net Change CRSPPositive Net Change
biotechnology biotechs earnings-preview gene-therapy pharmaceuticals